NECFA
RPTX

New England Capital Financial Advisors’s Repare Therapeutics RPTX Stock Holding History

New England Capital Financial Advisors’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12
Closed -$119 – 427
2023
Q1 		$119 Hold
12
– – ﹤0.01% 422
2022
Q4 		$142 Buy
+12
New +$180 ﹤0.01% 423

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

New England Capital Financial Advisors's RPTX Position: Q2 2023 in Review

New England Capital Financial Advisors sold out of Repare Therapeutics (RPTX) in Q2 2023, closing a stake of 12 shares — an estimated $119 sold.

New England Capital Financial Advisors first reported a position in RPTX in Q4 2022 and held it in 2 quarters. The position peaked at $142 in Q4 2022. 78 funds tracked by Wall St. Rank hold RPTX as of Q2 2023.

  • New England Capital Financial Advisors reported no remaining Repare Therapeutics position as of Q2 2023 after selling out during the quarter.
  • New England Capital Financial Advisors sold 12 Repare Therapeutics shares in Q2 2023, an estimated $119.
  • New England Capital Financial Advisors first reported a position in Repare Therapeutics in Q4 2022 and held it in 2 quarters.
  • New England Capital Financial Advisors's Repare Therapeutics position peaked at $142 in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Repare Therapeutics as of Q2 2023.

Based on New England Capital Financial Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.